Sound journalism, grounded in facts and Biblical truth | Donate

A new punch to a parasitic problem

By the Numbers

Illustration by Krieg Barrie

A new punch to a parasitic problem
You have {{ remainingArticles }} free {{ counterWords }} remaining. You've read all of your free articles.

Full access isn’t far.

We can’t release more of our sound journalism and commentary without a subscription, but we can make it easy for you to come aboard.

Get into news that is grounded in facts and Biblical truth for as low as $3.99 per month.


Already a member? Sign in.


The number of years the world’s first effective malaria vaccine, Glaxo­SmithKline-made Mosquirix, spent in development before the World Health Organization (WHO) approved its use on Oct. 6. French physician Alphonse Laveran discovered the parasite responsible for malaria in 1880, and scientists have been trying to control the disease ever since. According to clinical trials, Mosquirix demonstrated a 50 percent efficacy against malaria—well short of the WHO goal. But when combined with other malaria controls, the new vaccine significantly reduced the death and suffering brought about by the parasite


The efficacy standard set by the World Health Organization. Another vaccine in development called R21 posted a 77 percent efficacy this year in early tests.


The number of people who die of malaria each year.


The number of African children who die of malaria each year.


The number of people in three African ­countries who have received Mosquirix already.


The number of doses GlaxoSmithKline said it can produce annually charging 5 percent above the cost of production.


Please wait while we load the latest comments...


Please register, subscribe, or login to comment on this article.